董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lota Zoth | 女 | Director | 62 | 29.61万美元 | 未持股 | 2022-04-29 |
| Kenneth Hillan | 男 | Director | 61 | 26.56万美元 | 未持股 | 2022-04-29 |
| Natalie Sacks | 女 | Director | 57 | 25.89万美元 | 未持股 | 2022-04-29 |
| Kelvin Neu | 男 | Director | 48 | 52.85万美元 | 未持股 | 2022-04-29 |
| Susan Mahony | 女 | Director | 57 | 26.36万美元 | 未持股 | 2022-04-29 |
| Troy M. Cox | 男 | Director | 57 | 26.24万美元 | 未持股 | 2022-04-29 |
| Kenneth Galbraith | 男 | President, Chief Executive Officer and Chair of Board | 59 | 未披露 | 未持股 | 2022-04-29 |
| Hollings C. Renton | 男 | Director | 75 | 26.11万美元 | 未持股 | 2022-04-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Neil Klompas | 男 | Chief Operating Officer | 50 | 188.71万美元 | 未持股 | 2022-04-29 |
| Christopher Astle | 男 | Senior Vice President, Chief Financial Officer | 42 | 未披露 | 未持股 | 2022-04-29 |
| Kenneth Galbraith | 男 | President, Chief Executive Officer and Chair of Board | 59 | 未披露 | 未持股 | 2022-04-29 |
| Neil Josephson | 男 | Chief Medical Officer | 61 | 未披露 | 未持股 | 2022-04-29 |
董事简历
中英对照 | 中文 | 英文- Lota Zoth
-
Lota Zoth，自2016年1月起担任公司董事。在过去30多年的职业生涯中，Ms. Zoth曾在多家商业公司担任高级财务职务包括担任MedImmune首席财务官直至2007年公司被AstraZeneca收购。2002年加入MedImmune，Ms. Zoth曾担任PSINet Inc高级副总裁，财务总监兼总会计师，还曾在Sodexho Marriott Services, Inc., Marriott International以及PepsiCo, Incdan'ren担任副总裁，财务总监兼首席会计官。 Ms. Zoth还曾在Ernst & Young, LLP担任审计员，同时是一名注册会计师。Ms. Zoth获得了Texas Tech University会计学士学位。 她在Orexigen Therapeutics, Inc., Aeras, Circassia Pharmaceuticals, PLC以及NewLink Genetics Corporation的董事会任职。
Lota Zoth,has served as a member of enGene's Board and as chair of the Board's Audit Committee since December 18, 2023. Ms. Zoth is a Certified Public Accountant and has also served as a member of the board of directors of 89BIO, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, since June 2020. She has served as a member of the board of directors and as chair of the audit committee of Lumos Pharma, Inc. (Nasdaq: LUMO) (previously, NewLink Genetics Corporation), a biopharmaceutical company, since November 2012. She has also served as a member of the board of directors and chair of the audit committee of Inovio Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company, since January 2018 and August 2018, respectively. Ms. Zoth previously served as a member of the board of directors and chair of the audit committee of Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, from November 2016, as chair of the board of directors from September 2019 to January 2022 and as lead director since January 2022, until stepping down from the Zymeworks Inc. board in December 2023. In addition, she previously served as a member of the board of Spark Therapeutics, Inc., a gene therapy platform company, from January 2016 to December 2019, Circassia Pharmaceuticals, plc (LON: CIR), a specialty biopharmaceutical company, from February 2015 to February 2019, Orexigen Therapeutics, Inc., a biopharmaceutical company, from April 2012 to May 2019, Aeras, a nonprofit product development organization, from November 2011 to October 2018, Hyperion Therapeutics, Inc., a commercial-stage biopharmaceutical company, from February 2008 to May 2015 and Ikaria., Inc., a commercial stage biopharmaceutical company, from January 2008 to February 2014. Prior to her retirement, Ms. Zoth most recently served as Senior Vice President and Chief Financial Officer of MedImmune, Inc., a biotechnology company, from April 2004 to July 2007 and as Vice President, Controller & Chief Accounting Officer from August 2002 to April 2004. Ms. Zoth received her B.B.A. from Texas Tech University. - Lota Zoth，自2016年1月起担任公司董事。在过去30多年的职业生涯中，Ms. Zoth曾在多家商业公司担任高级财务职务包括担任MedImmune首席财务官直至2007年公司被AstraZeneca收购。2002年加入MedImmune，Ms. Zoth曾担任PSINet Inc高级副总裁，财务总监兼总会计师，还曾在Sodexho Marriott Services, Inc., Marriott International以及PepsiCo, Incdan'ren担任副总裁，财务总监兼首席会计官。 Ms. Zoth还曾在Ernst & Young, LLP担任审计员，同时是一名注册会计师。Ms. Zoth获得了Texas Tech University会计学士学位。 她在Orexigen Therapeutics, Inc., Aeras, Circassia Pharmaceuticals, PLC以及NewLink Genetics Corporation的董事会任职。
- Lota Zoth,has served as a member of enGene's Board and as chair of the Board's Audit Committee since December 18, 2023. Ms. Zoth is a Certified Public Accountant and has also served as a member of the board of directors of 89BIO, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, since June 2020. She has served as a member of the board of directors and as chair of the audit committee of Lumos Pharma, Inc. (Nasdaq: LUMO) (previously, NewLink Genetics Corporation), a biopharmaceutical company, since November 2012. She has also served as a member of the board of directors and chair of the audit committee of Inovio Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company, since January 2018 and August 2018, respectively. Ms. Zoth previously served as a member of the board of directors and chair of the audit committee of Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, from November 2016, as chair of the board of directors from September 2019 to January 2022 and as lead director since January 2022, until stepping down from the Zymeworks Inc. board in December 2023. In addition, she previously served as a member of the board of Spark Therapeutics, Inc., a gene therapy platform company, from January 2016 to December 2019, Circassia Pharmaceuticals, plc (LON: CIR), a specialty biopharmaceutical company, from February 2015 to February 2019, Orexigen Therapeutics, Inc., a biopharmaceutical company, from April 2012 to May 2019, Aeras, a nonprofit product development organization, from November 2011 to October 2018, Hyperion Therapeutics, Inc., a commercial-stage biopharmaceutical company, from February 2008 to May 2015 and Ikaria., Inc., a commercial stage biopharmaceutical company, from January 2008 to February 2014. Prior to her retirement, Ms. Zoth most recently served as Senior Vice President and Chief Financial Officer of MedImmune, Inc., a biotechnology company, from April 2004 to July 2007 and as Vice President, Controller & Chief Accounting Officer from August 2002 to April 2004. Ms. Zoth received her B.B.A. from Texas Tech University.
- Kenneth Hillan
-
Kenneth Hillan自2017年2月以来一直担任我们的董事会成员。Hillan博士自2011年10月起担任Achaogen，Inc.公司（一家公共生物制药公司）的首席执行官和董事会成员。在此之前，Hillan博士从2011年4月到2011年10月担任Achaogen’；的首席医疗官。在加入Achaogen之前，Hillan博士于1994年8月至2011年3月在Genentech，Inc.工作，该公司是一家制药公司，也是罗氏集团的成员。Hillan博士在Genentech逐步担任高级职位，最近的职位是从2010年4月到2011年3月担任亚太地区罗氏产品开发的高级副总裁和负责人，负责许多成功的药物批准，并领导Genentech免疫学的医疗和科学战略，组织生长和修复药物组合。Hillan博士还曾于2014年6月至2016年7月担任上市生物技术公司Relypsa，Inc.的董事会成员，该公司于2016年9月被Galencia AG以15亿美元收购。Hillan博士拥有工商管理硕士学位和工商管理硕士学位。英国格拉斯哥大学（University of Glasgow）医学院医学和外科学士学位。Hillan博士是Royal College of Surgeons的研究员，也是Royal College of Pathologists的研究员。
Kenneth Hillan has served as a member of Zymeworks Bc Inc. Board of Directors since February 2017. Dr. Hillan has served as Head of Therapeutics at 23andMe since February 2019. Dr. Hillan served on the board of directors of Achaogen, Inc., a public biopharmaceutical company, from October 2011 until April 2019. Dr. Hillan served as Achaogen's President and President, R&D from January 2018 to October 2018, as its Chief Executive Officer from October 2011 until December 2017, and as its Chief Medical Officer from April 2011 to July 2014. Prior to joining Achaogen, Dr. Hillan worked at Genentech, Inc., a pharmaceutical company and a member of the Roche Group, from August 1994 to March 2011. Dr. Hillan held progressively senior roles at Genentech, most recently holding the position of Senior Vice President & Head of Roche Product Development, Asia Pacific from April 2010 to March 2011, and was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech's immunology, tissue growth and repair drug portfolio. Dr. Hillan has served on the board of directors of Sangamo Therapeutics, Inc. since September 2020, and served on the board of directors of Relypsa, Inc., a publicly traded biotechnology company that was acquired in September 2016 by Galencia AG for $1.5 billion, from June 2014 to September 2016. Dr. Hillan has an M.B. and a Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow in the United Kingdom. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists. Dr. Hillan is a resident of California, USA. - Kenneth Hillan自2017年2月以来一直担任我们的董事会成员。Hillan博士自2011年10月起担任Achaogen，Inc.公司（一家公共生物制药公司）的首席执行官和董事会成员。在此之前，Hillan博士从2011年4月到2011年10月担任Achaogen’；的首席医疗官。在加入Achaogen之前，Hillan博士于1994年8月至2011年3月在Genentech，Inc.工作，该公司是一家制药公司，也是罗氏集团的成员。Hillan博士在Genentech逐步担任高级职位，最近的职位是从2010年4月到2011年3月担任亚太地区罗氏产品开发的高级副总裁和负责人，负责许多成功的药物批准，并领导Genentech免疫学的医疗和科学战略，组织生长和修复药物组合。Hillan博士还曾于2014年6月至2016年7月担任上市生物技术公司Relypsa，Inc.的董事会成员，该公司于2016年9月被Galencia AG以15亿美元收购。Hillan博士拥有工商管理硕士学位和工商管理硕士学位。英国格拉斯哥大学（University of Glasgow）医学院医学和外科学士学位。Hillan博士是Royal College of Surgeons的研究员，也是Royal College of Pathologists的研究员。
- Kenneth Hillan has served as a member of Zymeworks Bc Inc. Board of Directors since February 2017. Dr. Hillan has served as Head of Therapeutics at 23andMe since February 2019. Dr. Hillan served on the board of directors of Achaogen, Inc., a public biopharmaceutical company, from October 2011 until April 2019. Dr. Hillan served as Achaogen's President and President, R&D from January 2018 to October 2018, as its Chief Executive Officer from October 2011 until December 2017, and as its Chief Medical Officer from April 2011 to July 2014. Prior to joining Achaogen, Dr. Hillan worked at Genentech, Inc., a pharmaceutical company and a member of the Roche Group, from August 1994 to March 2011. Dr. Hillan held progressively senior roles at Genentech, most recently holding the position of Senior Vice President & Head of Roche Product Development, Asia Pacific from April 2010 to March 2011, and was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech's immunology, tissue growth and repair drug portfolio. Dr. Hillan has served on the board of directors of Sangamo Therapeutics, Inc. since September 2020, and served on the board of directors of Relypsa, Inc., a publicly traded biotechnology company that was acquired in September 2016 by Galencia AG for $1.5 billion, from June 2014 to September 2016. Dr. Hillan has an M.B. and a Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow in the United Kingdom. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists. Dr. Hillan is a resident of California, USA.
- Natalie Sacks
-
Natalie Sacks自2018年10月起担任首席医疗官。2016年9月至2018年9月，萨克斯博士担任免疫治疗公司AduroBiotech，Inc.的首席医疗官。加入Aduro之前，她曾于2011年4月至2014年2月担任Onyx Pharmaceuticals临床开发Vice President，该公司被生物制药公司Amgen收购，在Kyprolis的开发和批准过程中，她发挥了关键作用，FDA批准的治疗复发或难治性多发性骨髓瘤的疗法，以及在业务发展战略中。2009年9月至2011年3月，她担任基因组学制药公司Exelixis，Inc.的临床研究Vice President。Sacks从2002年11月到2009年4月担任Cell Genesys，Inc.（一家免疫肿瘤公司）临床开发Vice President。Sacks博士目前担任上市公司Zymeworks，Inc.（NYSE:ZYME）和Caribou Biosciences，Inc.的董事会成员。Sacks博士曾在学术机构和公司担任各种研究和分析角色，包括马萨诸塞州总医院，宾夕法尼亚医学院和ICI-Stuart Pharmaceuticals。从2004年到2016年，Sacks博士曾担任加州大学旧金山分校血液学/肿瘤学部门的医学助理临床教授。她持有Bryn Mawr College的数学学士学位、Harvard University School of Public Health的生物统计学硕士学位、the University of Pennsylvania School of Medicine的医学博士学位。
Natalie Sacks has served as a member of Zymeworks Bc Inc. Board of Directors since August 2017. Dr. Sacks is a trained oncologist, and has served as the Chief Medical Officer of Harpoon Therapeutics, Inc. since October 2018. She has served as a director on the board of Caribou Biosciences, Inc., a genome editing company, since May 2018 and on the board of STipe Therapeutics since April 2020. Prior to joining Harpoon, Dr. Sacks served as Chief Medical Officer of Aduro Biotech from September 2016 until September 2018. Previously, she was Vice President of Clinical Development at Onyx Pharmaceuticals (acquired by Amgen Inc.), where she played a key role in the development and approval of Kyprolis, an FDA-approved therapy for the treatment of multiple myeloma. Prior to that, she served as Vice President of Clinical Research for Exelixis where she directed the development of a portfolio of small molecules, including late-stage development of Cometriq. In addition to her industry experience, Dr. Sacks held a faculty appointment at the University of California, San Francisco, as an assistant clinical professor of medicine in the Division of Hematology/Oncology from 2003 to 2016. She received her M.D. from the University of Pennsylvania School of Medicine, her M.S. in Biostatistics from Harvard University School of Public Health and her B.A. in Mathematics from Bryn Mawr College. Dr. Sacks is a resident of California, USA. - Natalie Sacks自2018年10月起担任首席医疗官。2016年9月至2018年9月，萨克斯博士担任免疫治疗公司AduroBiotech，Inc.的首席医疗官。加入Aduro之前，她曾于2011年4月至2014年2月担任Onyx Pharmaceuticals临床开发Vice President，该公司被生物制药公司Amgen收购，在Kyprolis的开发和批准过程中，她发挥了关键作用，FDA批准的治疗复发或难治性多发性骨髓瘤的疗法，以及在业务发展战略中。2009年9月至2011年3月，她担任基因组学制药公司Exelixis，Inc.的临床研究Vice President。Sacks从2002年11月到2009年4月担任Cell Genesys，Inc.（一家免疫肿瘤公司）临床开发Vice President。Sacks博士目前担任上市公司Zymeworks，Inc.（NYSE:ZYME）和Caribou Biosciences，Inc.的董事会成员。Sacks博士曾在学术机构和公司担任各种研究和分析角色，包括马萨诸塞州总医院，宾夕法尼亚医学院和ICI-Stuart Pharmaceuticals。从2004年到2016年，Sacks博士曾担任加州大学旧金山分校血液学/肿瘤学部门的医学助理临床教授。她持有Bryn Mawr College的数学学士学位、Harvard University School of Public Health的生物统计学硕士学位、the University of Pennsylvania School of Medicine的医学博士学位。
- Natalie Sacks has served as a member of Zymeworks Bc Inc. Board of Directors since August 2017. Dr. Sacks is a trained oncologist, and has served as the Chief Medical Officer of Harpoon Therapeutics, Inc. since October 2018. She has served as a director on the board of Caribou Biosciences, Inc., a genome editing company, since May 2018 and on the board of STipe Therapeutics since April 2020. Prior to joining Harpoon, Dr. Sacks served as Chief Medical Officer of Aduro Biotech from September 2016 until September 2018. Previously, she was Vice President of Clinical Development at Onyx Pharmaceuticals (acquired by Amgen Inc.), where she played a key role in the development and approval of Kyprolis, an FDA-approved therapy for the treatment of multiple myeloma. Prior to that, she served as Vice President of Clinical Research for Exelixis where she directed the development of a portfolio of small molecules, including late-stage development of Cometriq. In addition to her industry experience, Dr. Sacks held a faculty appointment at the University of California, San Francisco, as an assistant clinical professor of medicine in the Division of Hematology/Oncology from 2003 to 2016. She received her M.D. from the University of Pennsylvania School of Medicine, her M.S. in Biostatistics from Harvard University School of Public Health and her B.A. in Mathematics from Bryn Mawr College. Dr. Sacks is a resident of California, USA.
- Kelvin Neu
-
Kelvin Neu是贝克兄弟公司的合伙人。Advisors LP，注册投资顾问。Neu博士自2020年3月起担任生物技术公司ZymeworksInc.的董事会成员，自2019年7月起担任生物制药公司IGMBiosciences，Inc.的董事会成员，也是IGM&8217；的研究和临床开发委员会成员。Neu博士此前曾在Idera Pharmaceuticals、Aquinox Pharmaceuticals和XOMA Corporation董事会任职。Neu博士在普林斯顿大学（Princeton University）以优异成绩获得A.B.Summa，在那里他因首次在分子生物系毕业而获得Khoury奖。在进入普林斯顿大学之前，Neu博士在他的祖国新加坡的军队中服役了两年半。Neu博士在哈佛医学院（Harvard Medical School-MIT Health Sciences and Technology Program）获得医学博士学位，并在斯坦福大学（Stanford University）的免疫学博士课程中花了三年时间，担任霍华德·休斯医学研究所研究员。
Kelvin Neu has served as a member of Zymeworks Bc Inc. Board of Directors since March 2020. Dr. Neu was a Partner at Baker Bros. Advisors LP, a registered investment adviser, from April 2004 until January 2021. Dr. Neu previously served on the board of directors of IGM Biosciences, Prelude Therapeutics, Idera Pharmaceuticals, Aquinox Pharmaceuticals and XOMA Corporation. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an A.B. (summa cum laude) from Princeton University, where he was awarded the Khoury Prize for graduating first in his department of Molecular Biology. Prior to attending Princeton, Dr. Neu served for two and a half years in the military of his native Singapore. Dr. Neu is a resident of Singapore. - Kelvin Neu是贝克兄弟公司的合伙人。Advisors LP，注册投资顾问。Neu博士自2020年3月起担任生物技术公司ZymeworksInc.的董事会成员，自2019年7月起担任生物制药公司IGMBiosciences，Inc.的董事会成员，也是IGM&8217；的研究和临床开发委员会成员。Neu博士此前曾在Idera Pharmaceuticals、Aquinox Pharmaceuticals和XOMA Corporation董事会任职。Neu博士在普林斯顿大学（Princeton University）以优异成绩获得A.B.Summa，在那里他因首次在分子生物系毕业而获得Khoury奖。在进入普林斯顿大学之前，Neu博士在他的祖国新加坡的军队中服役了两年半。Neu博士在哈佛医学院（Harvard Medical School-MIT Health Sciences and Technology Program）获得医学博士学位，并在斯坦福大学（Stanford University）的免疫学博士课程中花了三年时间，担任霍华德·休斯医学研究所研究员。
- Kelvin Neu has served as a member of Zymeworks Bc Inc. Board of Directors since March 2020. Dr. Neu was a Partner at Baker Bros. Advisors LP, a registered investment adviser, from April 2004 until January 2021. Dr. Neu previously served on the board of directors of IGM Biosciences, Prelude Therapeutics, Idera Pharmaceuticals, Aquinox Pharmaceuticals and XOMA Corporation. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an A.B. (summa cum laude) from Princeton University, where he was awarded the Khoury Prize for graduating first in his department of Molecular Biology. Prior to attending Princeton, Dr. Neu served for two and a half years in the military of his native Singapore. Dr. Neu is a resident of Singapore.
- Susan Mahony
-
Susan Mahony加入Assembly Biosciences, Inc.2017年12月加入董事会。从2011年到2018年8月退休，Mahony博士担任Lilly Oncology的高级副总裁兼总裁，以及Lilly的执行委员会成员。在此之前，从2000年到2011年，Mahony博士在礼来公司担任多种领导职务，包括人力资源和多样性高级副总裁、礼来加拿大公司总裁兼总经理、全球发展执行董事。Mahony博士于1995年至2000年在百时美施宝公司（Bristol-Myers Squibb Company）、Amgen Limited（1991年至1995年）、Schering Plough（1989年至1991年）从事销售和营销工作。Mahony博士是Vifor Pharma、Zymeworks Inc.和Horizon Therapeutics plc的董事会成员，这些公司都是上市公司。Mahony博士拥有药剂学学士学位和博士学位，并获得阿斯顿大学（Aston University）荣誉博士学位，以及伦敦商学院（London Business School）的工商管理硕士学位。
Susan Mahony,serves on the board of directors of Zymeworks Inc., a public biopharma company and Assembly Biosciences, Inc., a public biotechnology company. She served on the board of directors of Vifor Pharma AG, a public pharmaceutical company, from May 2019 until its acquisition by CSL Limited in August 2022. Previously, Dr. Mahony served as senior vice president and president of Lilly Oncology and was a member of the executive committee at Eli Lilly and Company from 2009 until her retirement in August 2018. Prior to that, Dr. Mahony served in a variety of leadership roles at Eli Lilly and Company, including senior vice president, human resources and diversity; president and general manager, Lilly Canada; and executive director, global brand development. Dr. Mahony worked in sales and marketing at Bristol-Myers Squibb Company from 1995 to 2000, at Amgen Limited from 1991 to 1995, and at Schering Plough from 1989 to 1991. Dr. Mahony also serves on the board of Chordoma Foundation, a nonprofit organization dedicated to improving the lives of those affected by chordoma. She earned bachelor of science and doctor of philosophy degrees in pharmacy from Aston University, as well as a master of business administration degree from London Business School. She was awarded an honorary doctorate from Aston University. - Susan Mahony加入Assembly Biosciences, Inc.2017年12月加入董事会。从2011年到2018年8月退休，Mahony博士担任Lilly Oncology的高级副总裁兼总裁，以及Lilly的执行委员会成员。在此之前，从2000年到2011年，Mahony博士在礼来公司担任多种领导职务，包括人力资源和多样性高级副总裁、礼来加拿大公司总裁兼总经理、全球发展执行董事。Mahony博士于1995年至2000年在百时美施宝公司（Bristol-Myers Squibb Company）、Amgen Limited（1991年至1995年）、Schering Plough（1989年至1991年）从事销售和营销工作。Mahony博士是Vifor Pharma、Zymeworks Inc.和Horizon Therapeutics plc的董事会成员，这些公司都是上市公司。Mahony博士拥有药剂学学士学位和博士学位，并获得阿斯顿大学（Aston University）荣誉博士学位，以及伦敦商学院（London Business School）的工商管理硕士学位。
- Susan Mahony,serves on the board of directors of Zymeworks Inc., a public biopharma company and Assembly Biosciences, Inc., a public biotechnology company. She served on the board of directors of Vifor Pharma AG, a public pharmaceutical company, from May 2019 until its acquisition by CSL Limited in August 2022. Previously, Dr. Mahony served as senior vice president and president of Lilly Oncology and was a member of the executive committee at Eli Lilly and Company from 2009 until her retirement in August 2018. Prior to that, Dr. Mahony served in a variety of leadership roles at Eli Lilly and Company, including senior vice president, human resources and diversity; president and general manager, Lilly Canada; and executive director, global brand development. Dr. Mahony worked in sales and marketing at Bristol-Myers Squibb Company from 1995 to 2000, at Amgen Limited from 1991 to 1995, and at Schering Plough from 1989 to 1991. Dr. Mahony also serves on the board of Chordoma Foundation, a nonprofit organization dedicated to improving the lives of those affected by chordoma. She earned bachelor of science and doctor of philosophy degrees in pharmacy from Aston University, as well as a master of business administration degree from London Business School. She was awarded an honorary doctorate from Aston University.
- Troy M. Cox
-
Troy M.Cox自2019年6月以来一直担任我们的董事会成员。Cox先生于2017年2月至2019年2月担任FoundationMedicine，Inc.首席执行官，于2017年2月至2018年7月担任Foundation Medicine’；S董事会成员，并于2018年2月至2018年7月担任Foundation Medicine总裁。在加入Foundation Medicine之前，Cox先生于2010年2月至2017年2月担任Genentech，Inc.销售与营销高级副总裁。在加入Genentech之前，Cox先生曾担任UCB S.A.的CNS运营总裁，负责开发和商业化主要与中枢神经系统有关的疾病的疗法。在加入UCB Biopharma之前，Cox先生在Sanofi-Aventis和Schering-Plough担任高级商业领导职务。Cox先生自2021年2月起担任CM Life Sciences IIInc.董事会成员。Cox先生拥有肯塔基大学的金融学学士学位和密苏里大学的工商管理硕士学位。考克斯先生是美国马萨诸塞州的居民。
Troy M. Cox has served as a member of Zymeworks Bc Inc. Board of Directors since June 2019. Mr. Cox served as Chief Executive Officer of Foundation Medicine, Inc. from February 2017 through February 2019, as a member of Foundation Medicine's board of directors from February 2017 until July 2018, and in the additional role of President of Foundation Medicine from February 2018 until July 2018. Prior to Foundation Medicine, Mr. Cox served as Senior Vice President, Sales & Marketing at Genentech, Inc. from February 2010 until February 2017. Before joining Genentech, Mr. Cox served as President of CNS operations at UCB S.A., with responsibility for developing and commercializing therapeutics for diseases primarily related to the central nervous system. Prior to UCB BioPharma, Mr. Cox held senior commercial leadership roles with Sanofi-Aventis and Schering-Plough. Mr. Cox serves on the board of directors of SomaLogic, Inc. and SOPHiA GENETICS SA. Mr. Cox received a B.B.A. in finance from the University of Kentucky and an M.B.A. from the University of Missouri. Mr. Cox is a resident of Florida, USA. - Troy M.Cox自2019年6月以来一直担任我们的董事会成员。Cox先生于2017年2月至2019年2月担任FoundationMedicine，Inc.首席执行官，于2017年2月至2018年7月担任Foundation Medicine’；S董事会成员，并于2018年2月至2018年7月担任Foundation Medicine总裁。在加入Foundation Medicine之前，Cox先生于2010年2月至2017年2月担任Genentech，Inc.销售与营销高级副总裁。在加入Genentech之前，Cox先生曾担任UCB S.A.的CNS运营总裁，负责开发和商业化主要与中枢神经系统有关的疾病的疗法。在加入UCB Biopharma之前，Cox先生在Sanofi-Aventis和Schering-Plough担任高级商业领导职务。Cox先生自2021年2月起担任CM Life Sciences IIInc.董事会成员。Cox先生拥有肯塔基大学的金融学学士学位和密苏里大学的工商管理硕士学位。考克斯先生是美国马萨诸塞州的居民。
- Troy M. Cox has served as a member of Zymeworks Bc Inc. Board of Directors since June 2019. Mr. Cox served as Chief Executive Officer of Foundation Medicine, Inc. from February 2017 through February 2019, as a member of Foundation Medicine's board of directors from February 2017 until July 2018, and in the additional role of President of Foundation Medicine from February 2018 until July 2018. Prior to Foundation Medicine, Mr. Cox served as Senior Vice President, Sales & Marketing at Genentech, Inc. from February 2010 until February 2017. Before joining Genentech, Mr. Cox served as President of CNS operations at UCB S.A., with responsibility for developing and commercializing therapeutics for diseases primarily related to the central nervous system. Prior to UCB BioPharma, Mr. Cox held senior commercial leadership roles with Sanofi-Aventis and Schering-Plough. Mr. Cox serves on the board of directors of SomaLogic, Inc. and SOPHiA GENETICS SA. Mr. Cox received a B.B.A. in finance from the University of Kentucky and an M.B.A. from the University of Missouri. Mr. Cox is a resident of Florida, USA.
- Kenneth Galbraith
-
Kenneth Galbraith历任Zymeworks Bc.总裁、首席执行官兼Zymeworks Bc.董事会主席至2022年1月。Galbraith先生是Five Corners Capital，Inc.的董事总经理，该公司是他于2013年创立的。最近，他于2021年4月至2022年1月在Syncona有限公司担任驻场执行官。2019年4月至2020年11月，他担任上市公司Liminal BioSciences Inc.（前身为Prometic Life Sciences Inc.）的首席执行官，并于2020年11月至2021年2月继续担任该公司的顾问。2017年6月至2019年4月，他还担任Fairhaven Pharmaceuticals Inc.的首席执行官。Galbraith先生于2008年7月至2022年1月担任MacroGenics，Inc.的董事，并于2017年1月起担任Profound Medical Corp.的董事，这两家公司都是上市公司。他还担任过几家私营公司的董事。此前，他于2007年加入Ventures West Capital，并于2013年创立了Five Corners Capital Inc.，负责管理Ventures West投资基金的持续运营。Galbraith先生在生物技术、医疗器械、制药和医疗保健等行业的公司担任执行董事、董事、投资者和顾问等职务时拥有30多年的经验。Galbraith先生在不列颠哥伦比亚大学获得了Comm.学士学位。Galbraith先生居住在联合王国剑桥。
Kenneth Galbraith has served as Zymeworks Bc Inc. President, Chief Executive Officer and Chair of Zymeworks Bc Inc. Board of Directors since January 2022. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013. Most recently he served as Executive in Residence at Syncona Limited from April 2021 until January 2022. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith served as a director of MacroGenics, Inc. from July 2008 until January 2022, and has served as a director of Profound Medical Corp. since January 2017, both of which are publicly held companies. He has also served as a director of several privately held companies. Previously, he joined Ventures West Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures West Investment Funds. Mr. Galbraith has over 30 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia. Mr. Galbraith resides in Cambridge, United Kingdom. - Kenneth Galbraith历任Zymeworks Bc.总裁、首席执行官兼Zymeworks Bc.董事会主席至2022年1月。Galbraith先生是Five Corners Capital，Inc.的董事总经理，该公司是他于2013年创立的。最近，他于2021年4月至2022年1月在Syncona有限公司担任驻场执行官。2019年4月至2020年11月，他担任上市公司Liminal BioSciences Inc.（前身为Prometic Life Sciences Inc.）的首席执行官，并于2020年11月至2021年2月继续担任该公司的顾问。2017年6月至2019年4月，他还担任Fairhaven Pharmaceuticals Inc.的首席执行官。Galbraith先生于2008年7月至2022年1月担任MacroGenics，Inc.的董事，并于2017年1月起担任Profound Medical Corp.的董事，这两家公司都是上市公司。他还担任过几家私营公司的董事。此前，他于2007年加入Ventures West Capital，并于2013年创立了Five Corners Capital Inc.，负责管理Ventures West投资基金的持续运营。Galbraith先生在生物技术、医疗器械、制药和医疗保健等行业的公司担任执行董事、董事、投资者和顾问等职务时拥有30多年的经验。Galbraith先生在不列颠哥伦比亚大学获得了Comm.学士学位。Galbraith先生居住在联合王国剑桥。
- Kenneth Galbraith has served as Zymeworks Bc Inc. President, Chief Executive Officer and Chair of Zymeworks Bc Inc. Board of Directors since January 2022. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013. Most recently he served as Executive in Residence at Syncona Limited from April 2021 until January 2022. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith served as a director of MacroGenics, Inc. from July 2008 until January 2022, and has served as a director of Profound Medical Corp. since January 2017, both of which are publicly held companies. He has also served as a director of several privately held companies. Previously, he joined Ventures West Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures West Investment Funds. Mr. Galbraith has over 30 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia. Mr. Galbraith resides in Cambridge, United Kingdom.
- Hollings C. Renton
-
Hollings C. Renton于2000年3月加入本公司出任董事。2008年3月从Onyx制药公司（一家生物制药和生物疗法公司）退休，自1992年4月起担任董事，于1993年3月成为总裁兼首席执行官，于2003年6月成为董事会主席。从1991年到1993年，担任Chiron公司（制药公司）的总裁兼首席营运官，随后公司收购Cetus Corporation。在收购之前，自1990年至1991年担任Cetus Corporation的总裁，自1987年至1990年担任首席营运官。亦担任Affymax公司，Rigel制药和Portola制药公司的董事局成员。
Hollings C. Renton has served as a member of Zymeworks Bc Inc. Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company,from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies, Portola Pharmaceuticals Inc., where he had also been board chairman (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. Mr. Renton is a resident of California, USA. - Hollings C. Renton于2000年3月加入本公司出任董事。2008年3月从Onyx制药公司（一家生物制药和生物疗法公司）退休，自1992年4月起担任董事，于1993年3月成为总裁兼首席执行官，于2003年6月成为董事会主席。从1991年到1993年，担任Chiron公司（制药公司）的总裁兼首席营运官，随后公司收购Cetus Corporation。在收购之前，自1990年至1991年担任Cetus Corporation的总裁，自1987年至1990年担任首席营运官。亦担任Affymax公司，Rigel制药和Portola制药公司的董事局成员。
- Hollings C. Renton has served as a member of Zymeworks Bc Inc. Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company,from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies, Portola Pharmaceuticals Inc., where he had also been board chairman (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. Mr. Renton is a resident of California, USA.
高管简历
中英对照 | 中文 | 英文- Neil Klompas
Neil Klompas于2007年3月加入ZymeworksInc.，目前担任我们的首席财务官。除了财务责任，并与我们的总裁兼首席执行官一起，他管理我们的企业增长计划。在加入ZymeworksInc.之前，他曾在加拿大和美国的毕马威会计师事务所（KPMG LLP）工作，最近的一次是从2005年到2007年在新泽西州普林斯顿的毕马威制药、生物技术和医疗设备并购交易服务公司（KPMG’s Pharmaceuticals，Biotechnology and Medical Device M&A Transaction Services Practice）工作，为许多交易提供咨询，包括并购、资产剥离和战略联盟。在此之前，从2000年到2005年，Klompas先生在毕马威会计师事务所（KPMG）的加拿大生物技术与制药业务在保证，评估与税收领域任职。Klompas先生是一名特许专业会计师，也是British Columbia特许专业会计师协会成员。Klompas先生还持有British Columbia大学微生物学和免疫学学位，并担任Camosun学院生物技术和化学系顾问委员会成员，以及加拿大基因治疗基金会和私营生物技术公司Ovensa Inc.的董事。
Neil Klompas joined Zymeworks in March 2007 and currently serves as Zymeworks Bc Inc. Chief Operating Officer. Previously, Mr. Klompas served as Zymeworks Bc Inc. Chief Financial Officer from December 2007 to February 2022 and as Zymeworks Bc Inc. Executive Vice President, Business Operations from September 2019 until January 2022. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG's Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG's Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the Board of Liminal BioSciences Inc. (NASDAQ: LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia. He serves on the faculty advisory board for Biotechnology and Chemistry for Camosun College and as a member of the board of directors of Ovensa Inc., a private biotechnology company.- Neil Klompas于2007年3月加入ZymeworksInc.，目前担任我们的首席财务官。除了财务责任，并与我们的总裁兼首席执行官一起，他管理我们的企业增长计划。在加入ZymeworksInc.之前，他曾在加拿大和美国的毕马威会计师事务所（KPMG LLP）工作，最近的一次是从2005年到2007年在新泽西州普林斯顿的毕马威制药、生物技术和医疗设备并购交易服务公司（KPMG’s Pharmaceuticals，Biotechnology and Medical Device M&A Transaction Services Practice）工作，为许多交易提供咨询，包括并购、资产剥离和战略联盟。在此之前，从2000年到2005年，Klompas先生在毕马威会计师事务所（KPMG）的加拿大生物技术与制药业务在保证，评估与税收领域任职。Klompas先生是一名特许专业会计师，也是British Columbia特许专业会计师协会成员。Klompas先生还持有British Columbia大学微生物学和免疫学学位，并担任Camosun学院生物技术和化学系顾问委员会成员，以及加拿大基因治疗基金会和私营生物技术公司Ovensa Inc.的董事。
- Neil Klompas joined Zymeworks in March 2007 and currently serves as Zymeworks Bc Inc. Chief Operating Officer. Previously, Mr. Klompas served as Zymeworks Bc Inc. Chief Financial Officer from December 2007 to February 2022 and as Zymeworks Bc Inc. Executive Vice President, Business Operations from September 2019 until January 2022. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG's Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG's Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the Board of Liminal BioSciences Inc. (NASDAQ: LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia. He serves on the faculty advisory board for Biotechnology and Chemistry for Camosun College and as a member of the board of directors of Ovensa Inc., a private biotechnology company.
- Christopher Astle
Christopher Astle于2021年4月加入Zymeworks，并于2022年2月晋升为高级副总裁兼首席财务官。他此前于2021年4月至2022年2月担任Zymeworks Bc公司企业与商业财务执行董事。在加入Zymeworks之前，Astle博士于2020年3月至2021年3月在加拿大不列颠哥伦比亚省CFO中心担任首席财务官，于2019年4月至2020年2月在美国西雅图Alder BioPharmaceuticals Inc.担任副总裁财务Zymeworks。2017年8月至2020年1月，他担任英国伦敦精品金融咨询公司Think Forwards的首席执行官和创始人。Astle博士于2011年至2017年在艾尔建工作，包括于2016年7月至2017年7月担任国际事业部财务副副总裁，负责管理多个产品发布、并购交易和重组，拥有一支遍布60个国家的170人团队。他是一名英国特许会计师（ICAS），拥有英国伦敦普华永道审计与制药绩效改进咨询专业的资格，审计客户包括GSK。他是Oak Bay Biosciences（2020年至今）和Healome Therapeutics（2021年至今）两家私营生物技术公司的董事会成员。在英国期间，他曾担任2018年CFO议程会议主席、亨利商学院客座讲师以及英国会计奖评委。Astle博士拥有英国布里斯托尔大学有机化学博士学位和英国利物浦大学化学硕士学位。
Christopher Astle joined Zymeworks in April 2021 and was promoted to Senior Vice President and Chief Financial Officer in February 2022. He previously served as Zymeworks Bc Inc. Executive Director, Corporate and Commercial Finance from April 2021 to February 2022. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, USA from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, United Kingdom. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. He is a board member of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the United Kingdom, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK).- Christopher Astle于2021年4月加入Zymeworks，并于2022年2月晋升为高级副总裁兼首席财务官。他此前于2021年4月至2022年2月担任Zymeworks Bc公司企业与商业财务执行董事。在加入Zymeworks之前，Astle博士于2020年3月至2021年3月在加拿大不列颠哥伦比亚省CFO中心担任首席财务官，于2019年4月至2020年2月在美国西雅图Alder BioPharmaceuticals Inc.担任副总裁财务Zymeworks。2017年8月至2020年1月，他担任英国伦敦精品金融咨询公司Think Forwards的首席执行官和创始人。Astle博士于2011年至2017年在艾尔建工作，包括于2016年7月至2017年7月担任国际事业部财务副副总裁，负责管理多个产品发布、并购交易和重组，拥有一支遍布60个国家的170人团队。他是一名英国特许会计师（ICAS），拥有英国伦敦普华永道审计与制药绩效改进咨询专业的资格，审计客户包括GSK。他是Oak Bay Biosciences（2020年至今）和Healome Therapeutics（2021年至今）两家私营生物技术公司的董事会成员。在英国期间，他曾担任2018年CFO议程会议主席、亨利商学院客座讲师以及英国会计奖评委。Astle博士拥有英国布里斯托尔大学有机化学博士学位和英国利物浦大学化学硕士学位。
- Christopher Astle joined Zymeworks in April 2021 and was promoted to Senior Vice President and Chief Financial Officer in February 2022. He previously served as Zymeworks Bc Inc. Executive Director, Corporate and Commercial Finance from April 2021 to February 2022. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, USA from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, United Kingdom. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. He is a board member of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the United Kingdom, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK).
- Kenneth Galbraith
Kenneth Galbraith历任Zymeworks Bc.总裁、首席执行官兼Zymeworks Bc.董事会主席至2022年1月。Galbraith先生是Five Corners Capital，Inc.的董事总经理，该公司是他于2013年创立的。最近，他于2021年4月至2022年1月在Syncona有限公司担任驻场执行官。2019年4月至2020年11月，他担任上市公司Liminal BioSciences Inc.（前身为Prometic Life Sciences Inc.）的首席执行官，并于2020年11月至2021年2月继续担任该公司的顾问。2017年6月至2019年4月，他还担任Fairhaven Pharmaceuticals Inc.的首席执行官。Galbraith先生于2008年7月至2022年1月担任MacroGenics，Inc.的董事，并于2017年1月起担任Profound Medical Corp.的董事，这两家公司都是上市公司。他还担任过几家私营公司的董事。此前，他于2007年加入Ventures West Capital，并于2013年创立了Five Corners Capital Inc.，负责管理Ventures West投资基金的持续运营。Galbraith先生在生物技术、医疗器械、制药和医疗保健等行业的公司担任执行董事、董事、投资者和顾问等职务时拥有30多年的经验。Galbraith先生在不列颠哥伦比亚大学获得了Comm.学士学位。Galbraith先生居住在联合王国剑桥。
Kenneth Galbraith has served as Zymeworks Bc Inc. President, Chief Executive Officer and Chair of Zymeworks Bc Inc. Board of Directors since January 2022. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013. Most recently he served as Executive in Residence at Syncona Limited from April 2021 until January 2022. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith served as a director of MacroGenics, Inc. from July 2008 until January 2022, and has served as a director of Profound Medical Corp. since January 2017, both of which are publicly held companies. He has also served as a director of several privately held companies. Previously, he joined Ventures West Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures West Investment Funds. Mr. Galbraith has over 30 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia. Mr. Galbraith resides in Cambridge, United Kingdom.- Kenneth Galbraith历任Zymeworks Bc.总裁、首席执行官兼Zymeworks Bc.董事会主席至2022年1月。Galbraith先生是Five Corners Capital，Inc.的董事总经理，该公司是他于2013年创立的。最近，他于2021年4月至2022年1月在Syncona有限公司担任驻场执行官。2019年4月至2020年11月，他担任上市公司Liminal BioSciences Inc.（前身为Prometic Life Sciences Inc.）的首席执行官，并于2020年11月至2021年2月继续担任该公司的顾问。2017年6月至2019年4月，他还担任Fairhaven Pharmaceuticals Inc.的首席执行官。Galbraith先生于2008年7月至2022年1月担任MacroGenics，Inc.的董事，并于2017年1月起担任Profound Medical Corp.的董事，这两家公司都是上市公司。他还担任过几家私营公司的董事。此前，他于2007年加入Ventures West Capital，并于2013年创立了Five Corners Capital Inc.，负责管理Ventures West投资基金的持续运营。Galbraith先生在生物技术、医疗器械、制药和医疗保健等行业的公司担任执行董事、董事、投资者和顾问等职务时拥有30多年的经验。Galbraith先生在不列颠哥伦比亚大学获得了Comm.学士学位。Galbraith先生居住在联合王国剑桥。
- Kenneth Galbraith has served as Zymeworks Bc Inc. President, Chief Executive Officer and Chair of Zymeworks Bc Inc. Board of Directors since January 2022. Mr. Galbraith was a Managing Director at Five Corners Capital, Inc., which he founded in 2013. Most recently he served as Executive in Residence at Syncona Limited from April 2021 until January 2022. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.), a publicly held company, from April 2019 to November 2020, continuing as an advisor to that company from November 2020 to February 2021. He also served as Chief Executive Officer of Fairhaven Pharmaceuticals Inc. from June 2017 to April 2019. Mr. Galbraith served as a director of MacroGenics, Inc. from July 2008 until January 2022, and has served as a director of Profound Medical Corp. since January 2017, both of which are publicly held companies. He has also served as a director of several privately held companies. Previously, he joined Ventures West Capital in 2007 and founded Five Corners Capital Inc. in 2013 to manage the continued operations of the Ventures West Investment Funds. Mr. Galbraith has over 30 years of experience serving as an executive, director, investor and adviser to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith received his B.Comm. from the University of British Columbia. Mr. Galbraith resides in Cambridge, United Kingdom.
- Neil Josephson
Neil Josephson于2019年4月加入Zymeworks，自2021年11月起担任Zymeworks首席医疗官。Josephson博士于2019年4月至2020年8月担任Zymeworks Bc公司临床研究副总裁、Zymeworks Bc公司2020年8月至2021年11月担任副总裁临床研究高级Zymeworks、2021年5月至2021年11月担任Zymeworks Bc公司临时首席医疗官。在加入Zymeworks之前，他曾在西雅图遗传学公司担任临床开发副总裁职务，2013-2019年期间曾参与多个早期和后期项目，包括牵头批准ADCETRIS 治疗霍奇金淋巴瘤。2002-2013年，Josephson博士是华盛顿大学血液学部和普吉特海湾血液中心的全职教员，担任医学副教授和血友病护理项目主任。他在华盛顿大学完成了血液学和肿瘤学的研究金培训，并拥有哥伦比亚大学的医学博士学位和达特茅斯学院的生物学学士学位。
Neil Josephson joined Zymeworks in April 2019 and has served as Zymeworks Bc Inc. Chief Medical Officer since November 2021. Dr. Josephson served as Zymeworks Bc Inc. Vice President, Clinical Research from April 2019 until August 2020, as Zymeworks Bc Inc. Senior Vice President, Clinical Research from August 2020 to November 2021, and as Zymeworks Bc Inc. interim Chief Medical Officer from May 2021 until November 2021. Prior to joining Zymeworks he was a Vice President in Clinical Development at Seattle Genetics where he worked on multiple early and late-stage programs from 2013-2019, including leading the first line approval of ADCETRIS in Hodgkin Lymphoma. From 2002-2013 Dr. Josephson was a full-time faculty member of the Division of Hematology at the University of Washington and the Puget Sound Blood Center, serving as an Associate Professor of Medicine and the Director of Hemophilia Care Program. He completed fellowship training in Hematology and Oncology at the University of Washington and holds an M.D. degree from Columbia University an an A.B. in biology from Dartmouth College.- Neil Josephson于2019年4月加入Zymeworks，自2021年11月起担任Zymeworks首席医疗官。Josephson博士于2019年4月至2020年8月担任Zymeworks Bc公司临床研究副总裁、Zymeworks Bc公司2020年8月至2021年11月担任副总裁临床研究高级Zymeworks、2021年5月至2021年11月担任Zymeworks Bc公司临时首席医疗官。在加入Zymeworks之前，他曾在西雅图遗传学公司担任临床开发副总裁职务，2013-2019年期间曾参与多个早期和后期项目，包括牵头批准ADCETRIS 治疗霍奇金淋巴瘤。2002-2013年，Josephson博士是华盛顿大学血液学部和普吉特海湾血液中心的全职教员，担任医学副教授和血友病护理项目主任。他在华盛顿大学完成了血液学和肿瘤学的研究金培训，并拥有哥伦比亚大学的医学博士学位和达特茅斯学院的生物学学士学位。
- Neil Josephson joined Zymeworks in April 2019 and has served as Zymeworks Bc Inc. Chief Medical Officer since November 2021. Dr. Josephson served as Zymeworks Bc Inc. Vice President, Clinical Research from April 2019 until August 2020, as Zymeworks Bc Inc. Senior Vice President, Clinical Research from August 2020 to November 2021, and as Zymeworks Bc Inc. interim Chief Medical Officer from May 2021 until November 2021. Prior to joining Zymeworks he was a Vice President in Clinical Development at Seattle Genetics where he worked on multiple early and late-stage programs from 2013-2019, including leading the first line approval of ADCETRIS in Hodgkin Lymphoma. From 2002-2013 Dr. Josephson was a full-time faculty member of the Division of Hematology at the University of Washington and the Puget Sound Blood Center, serving as an Associate Professor of Medicine and the Director of Hemophilia Care Program. He completed fellowship training in Hematology and Oncology at the University of Washington and holds an M.D. degree from Columbia University an an A.B. in biology from Dartmouth College.